In the 20 years since the first report of a proteolysis targeting chimeric (PROTAC) molecule,
targeted protein degradation (TPD) technologies have attempted to revolutionize the fields …

Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of
traditional small-molecule inhibitors. Proteolysis-targeting chimera (PROTAC) technology …

Targeted protein degradation (TPD) has emerged as a promising approach for drug
development, particularly for undruggable targets. TPD technology has also been …

G-quadruplex (G4) binding proteins regulate important biological processes, but their
interaction networks are poorly understood. We report the first use of G4 as a warhead of a …

ABSTRACT RNA-based therapeutics are emerging as a powerful platform for the treatment
of multiple diseases. Currently, the two main categories of nucleic acid therapeutics …

The Hippo pathway is dysregulated in many different cancers, but point mutations in the
pathway are rare. Transcriptional co-activator with PDZ-binding motif (TAZ) and Yes …

The transcription factor FOXM1 that regulates multiple proliferation-related genes through
selective protein-DNA and protein–protein interactions is now considered an attractive …

Transcription factors (TFs) control numerous genes that are directly relevant to many human
disorders. However, developing specific reagents targeting TFs within intact cells is …

PROteolysis-TArgeting Chimeras (PROTACs) are a powerful class of drugs that selectively
degrade the proteins of interest (POIs) through cellular ubiquitination mechanisms. Estrogen …

SNAI1, a zinc finger transcription factor, not only acts as the master regulator of epithelial-
mesenchymal transition (EMT) but also functions as a driver of cancer progression, including …